Login to Your Account



Allos Plans NDA For Cancer Drug After Analysis Of Subset Results

By Kim Coghill


Friday, May 30, 2003
Allos Therapeutics Inc.'s stock soared 61.5 percent Thursday after the company said it would file a new drug application for a synthetic small molecule shown to double median survival time in breast cancer patients. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription